



**EDCTP**

*The power of sharing science*


# Building research & development capacity to combat neglected tropical diseases

**17 October 2023**

Michael Makanga | Executive Director | EDCTP



# Global Health EDCTP3 integrated approach & scope



# ■ Global Health EDCTP3 specific objectives


Five specific objectives:

1. Advance the development and use of new or improved health technologies for tackling infectious diseases by supporting the conduct of the clinical trials in sub-Saharan Africa
- 2. Strengthen research and innovation capacity and the national health research systems in sub-Saharan Africa**
3. Facilitate better alignment of countries around a common SRIA
4. Strengthen capacity for epidemic preparedness in sub-Saharan Africa
5. Promote networking and partnerships building North–South and South–South relationships with multiple private and public-sector organisations.

# EDCTP-supported activities in sub-Saharan Africa


October 2023

- French speaking countries
- Portuguese speaking countries
- English speaking countries



# Country involvement in clinical studies

October 2023



**38 sub-Saharan African countries** host recruitment centres/sites with EDCTP-funded clinical studies





# EDCTP Regional Networks of Excellence

## African countries

1. Angola
2. Benin
3. Botswana
4. Burkina Faso
5. Burundi
6. Cameroon
7. Congo
8. Cote d'Ivoire
9. Democratic Republic of the Congo
10. Eswatini
11. Ethiopia
12. Gabon
13. The Gambia
14. Ghana
15. Guinea
16. Kenya
17. Malawi
18. Mali
19. Mozambique
20. Namibia
21. Nigeria
22. Rwanda
23. Senegal
24. Sierra Leone
25. South Africa
26. South Sudan
27. Sudan
28. Tanzania
29. Togo
30. Uganda
31. Zambia
32. Zimbabwe

## European countries

1. Belgium
2. France
3. Germany
4. Netherlands
5. Portugal
6. Spain
7. Sweden
8. United Kingdom

-  **CANTAM3**  
Central Africa clinical research Network
-  **EACCR3**  
Eastern Africa Consortium for Clinical Research
-  **WANETAM3**  
West African Network for TB Aids and malaria
-  **TESA3**  
Trials of Excellence in Southern Africa



# EDCTP Fellowships and trainings (2003-2023)



Awarded **262 fellowship grants** to researchers from sub-Saharan Africa (56 EDCTP1; 206 EDCTP2)



Supported **151 fellows** through **Master's training in epidemiology and biostatistics**



Supported **1,381 trainees** from sub-Saharan Africa through EDCTP projects (460 EDCTP1; 921 EDCTP2)



Established an **EDCTP Alumni Network** and online platform




# EDCTP 1&2 fellowships

## Fellowship grants by disease


### EDCTP1

Grand Total:  
**56 grants**  
**€10.5 M**



### EDCTP2


Grand Total:  
**215 grants**  
**€52.4 M**





# Gender equality in science

**37% of the projects** in the EDCTP2 portfolio are led by a female:




**46%** of the 580 African academic trainees are female.

**39%** of the members of expert review committees for EDCTP calls evaluations are female.

# Strengthening ethics and regulatory capacity in Africa

2014-2022



EDCTP-supported ethics and regulatory projects are being conducted in **37 sub-Saharan African countries**.

Of these, activities focusing on regulatory strengthening are being conducted in **28 sub-Saharan countries**

# Bringing schistosomiasis treatment to preschool-age children

THE LANCET

---

## Efficacy, safety, and palatability of arpraziquantel (L-praziquantel) orodispersible tablets in children aged 3 months to 6 years infected with *Schistosoma* in Côte d'Ivoire and Kenya: an open-label, partly randomised, phase 3 trial

Eliézer K N'Goran\*, Maurice R Odiero\*, Ronald Assandé Aka, Mamadou Ouattara, N A David Aka, Bernhards Ogutu, Fredrick Rawago, Wilhelmina M Bagchus, Matthias Bödding, Elly Kourany-Lefoll, Aliona Tappert, Xiaoyan Yin, Deon Bezuidenhout, Henk Badenhorst, Eric Huber, Benjamin Dälken, Okba Haj-Ali Soflo

**DOI:** [https://doi.org/10.1016/S1473-3099\(23\)00048-8](https://doi.org/10.1016/S1473-3099(23)00048-8)

- Published in *The Lancet Infectious Diseases* in March 2023
- Led by the **Pediatric Praziquantel Consortium**, the PZQ4PSAC project is co-funded by EDCTP and the Global Health Innovative Technology (GHIT) Fund
- Results from the phase III trial showed excellent efficacy, achieving cure rates of 90% or above, and was safe and well-tolerated by young children.
- Submitted a request to EMA for a scientific opinion to facilitate the inclusion of arpraziquantel on the WHO list of prequalified medical products and accelerate regulatory approvals in affected countries.
- **ADOPT programme** (also co-funded by EDCTP and GHIT Fund): preparing for the large-scale delivery of the new medication and ensuring wide acceptance and equitable access for preschool-aged children.

# Thank you



**E D C T P**

Supported by the  
European Union



[www.edctp.org](http://www.edctp.org) | [media@edctp.org](mailto:media@edctp.org)